Literature DB >> 16145347

High rates of uninsured among HCV-positive individuals.

Janus P Ong1, Rochelle Collantes, Angela Pitts, Lisa Martin, Michael Sheridan, Zobair M Younossi.   

Abstract

BACKGROUND AND GOALS: There are no published data on the health insurance status of Hepatitis C virus (HCV)-positive individuals. To address this issue, we analyzed data from the Third National Health and Nutrition Examination Survey (NHANES III). STUDY: Individuals 18 years of age and older who participated in NHANES III were included in the study. We determined the rates of health insurance coverage according to HCV status. We also determined healthcare status and health service utilization according to health insurance status among HCV-positive persons.
RESULTS: HCV-positive individuals were more likely to be uninsured compared with those who were HCV-negative (29.6% vs. 12.2%, P = 0.0002). Among those with health insurance, HCV-positive individuals were more likely to have government insurance compared with those who were HCV-negative (42.9% vs. 27.6%, P < 0.005). Among HCV-positive individuals, being uninsured was associated with younger age, being unmarried, living in the South, Mexican-American race/ethnicity, and not graduating from high school. Additionally, the uninsured were less likely than their insured counterparts to identify a healthcare facility for sick or routine care, and less likely to have regular contact with a healthcare professional.
CONCLUSIONS: A high proportion of HCV-positive individuals are uninsured, and many HCV-positive individuals with health insurance have publicly funded insurance. This finding may have implications for access to health care and for liver-related disease outcomes in HCV-positive persons.

Entities:  

Mesh:

Year:  2005        PMID: 16145347     DOI: 10.1097/01.mcg.0000177258.95562.43

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

1.  Managing chronic hepatitis C in primary-care settings: more than antiviral therapy.

Authors:  Barry Zevin
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

Review 2.  Barriers to hepatitis C treatment.

Authors:  Christopher E McGowan; Michael W Fried
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

3.  Utility of evaluating HCV in an uninsured population.

Authors:  Indira Donepudi; Angelo Paredes; Sarah Hubbard; Chadi Awad; Richard K Sterling
Journal:  Dig Dis Sci       Date:  2014-11-05       Impact factor: 3.199

4.  A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.

Authors:  Sean J Haley; Mary Jeanne Kreek
Journal:  Am J Public Health       Date:  2015-01-20       Impact factor: 9.308

5.  Knowledge, attitudes, and beliefs of patients with chronic liver disease.

Authors:  Brett Burnham; Sherrie Wallington; Irene A Jillson; Holta Trandafili; Kirti Shetty; Judy Wang; Christopher A Loffredo
Journal:  Am J Health Behav       Date:  2014-09

6.  Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015.

Authors:  Monica L Kasting; Anna R Giuliano; Richard R Reich; Richard G Roetzheim; David R Nelson; Elizabeth Shenkman; Susan T Vadaparampil
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-27       Impact factor: 4.254

7.  Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study.

Authors:  Kyriakos Souliotis; Eirini Agapidaki; Manto Papageorgiou; Niki Voudouri; Xenophon Contiades
Journal:  Int J Equity Health       Date:  2017-06-14

Review 8.  The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

Authors:  N H Afdhal; S Zeuzem; R T Schooley; D L Thomas; J W Ward; A H Litwin; H Razavi; L Castera; T Poynard; A Muir; S H Mehta; L Dee; C Graham; D R Church; A H Talal; M S Sulkowski; I M Jacobson
Journal:  J Viral Hepat       Date:  2013-11       Impact factor: 3.728

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.